Identification of environmental and genetic factors that influence warfarin time in therapeutic range
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/267096 |
Resumo: | Warfarin is an oral anticoagulant prescribed to prevent and treat thromboembolic disorders. It has a narrow therapeutic window and must have its effect controlled. Prothrombin test, expressed in INR value, is used for dose management. Time in therapeutic range (TTR) is an important outcome of quality control of anticoagulation therapy and is influenced by several factors. The aim of this study was to identify genetic, demographic, and clinical factors that can potentially influence TTR. In total,422 patients using warfarin were investigated. Glibenclamide co-medication and presence of CYP2C9*2 and/or *3 alleles were associated with higher TTR, while amiodarone, acetaminophen and verapamil co-medication were associated with lower TTR. Our data suggest that TTR is influenced by co-medication and genetic factors. Thus, individuals in use of glibenclamide may need a more careful monitoring and genetic testing (CYP2C9*2 and/or *3 alleles) may improve the anticoagulation management. In addition, in order to reach and maintain the INR in the target for a longer period, it is better to discuss dose adjustment in office instead of by telephone assessment. Other studies are needed to confirm these results and to find more variables that could contribute to this important parameter. |
id |
UFRGS-2_988f52ce9d3520fc17fbb3f3524af508 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/267096 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Botton, Mariana RodriguesViola, Patrícia PachecoMeireles, Mariana RostBruxel, Estela MariaZuchinali, PriccilaBandinelli, ElianeRohde, Luis Eduardo PaimLeiria, Tiago Luiz LuzSalamoni, Joyce Yukie YamakawaGarbin, Arthur PereiraHutz, Mara Helena2023-11-14T03:23:29Z20201415-4757http://hdl.handle.net/10183/267096001158568Warfarin is an oral anticoagulant prescribed to prevent and treat thromboembolic disorders. It has a narrow therapeutic window and must have its effect controlled. Prothrombin test, expressed in INR value, is used for dose management. Time in therapeutic range (TTR) is an important outcome of quality control of anticoagulation therapy and is influenced by several factors. The aim of this study was to identify genetic, demographic, and clinical factors that can potentially influence TTR. In total,422 patients using warfarin were investigated. Glibenclamide co-medication and presence of CYP2C9*2 and/or *3 alleles were associated with higher TTR, while amiodarone, acetaminophen and verapamil co-medication were associated with lower TTR. Our data suggest that TTR is influenced by co-medication and genetic factors. Thus, individuals in use of glibenclamide may need a more careful monitoring and genetic testing (CYP2C9*2 and/or *3 alleles) may improve the anticoagulation management. In addition, in order to reach and maintain the INR in the target for a longer period, it is better to discuss dose adjustment in office instead of by telephone assessment. Other studies are needed to confirm these results and to find more variables that could contribute to this important parameter.application/pdfengGenetics and molecular biology. Ribeirão Preto. Vol. 43, no. 1 suppl. 2 (2020), e20190025, 5p.VarfarinaCYP2C9VKORC1ASPHTTRIdentification of environmental and genetic factors that influence warfarin time in therapeutic rangeinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/otherinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001158568.pdf.txt001158568.pdf.txtExtracted Texttext/plain0http://www.lume.ufrgs.br/bitstream/10183/267096/2/001158568.pdf.txtd41d8cd98f00b204e9800998ecf8427eMD52ORIGINAL001158568.pdfTexto completo (inglês)application/pdf9023513http://www.lume.ufrgs.br/bitstream/10183/267096/1/001158568.pdfc26f90d63e539bb3ab12260add46adb6MD5110183/2670962023-11-15 04:25:57.166108oai:www.lume.ufrgs.br:10183/267096Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-11-15T06:25:57Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Identification of environmental and genetic factors that influence warfarin time in therapeutic range |
title |
Identification of environmental and genetic factors that influence warfarin time in therapeutic range |
spellingShingle |
Identification of environmental and genetic factors that influence warfarin time in therapeutic range Botton, Mariana Rodrigues Varfarina CYP2C9 VKORC1 ASPH TTR |
title_short |
Identification of environmental and genetic factors that influence warfarin time in therapeutic range |
title_full |
Identification of environmental and genetic factors that influence warfarin time in therapeutic range |
title_fullStr |
Identification of environmental and genetic factors that influence warfarin time in therapeutic range |
title_full_unstemmed |
Identification of environmental and genetic factors that influence warfarin time in therapeutic range |
title_sort |
Identification of environmental and genetic factors that influence warfarin time in therapeutic range |
author |
Botton, Mariana Rodrigues |
author_facet |
Botton, Mariana Rodrigues Viola, Patrícia Pacheco Meireles, Mariana Rost Bruxel, Estela Maria Zuchinali, Priccila Bandinelli, Eliane Rohde, Luis Eduardo Paim Leiria, Tiago Luiz Luz Salamoni, Joyce Yukie Yamakawa Garbin, Arthur Pereira Hutz, Mara Helena |
author_role |
author |
author2 |
Viola, Patrícia Pacheco Meireles, Mariana Rost Bruxel, Estela Maria Zuchinali, Priccila Bandinelli, Eliane Rohde, Luis Eduardo Paim Leiria, Tiago Luiz Luz Salamoni, Joyce Yukie Yamakawa Garbin, Arthur Pereira Hutz, Mara Helena |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Botton, Mariana Rodrigues Viola, Patrícia Pacheco Meireles, Mariana Rost Bruxel, Estela Maria Zuchinali, Priccila Bandinelli, Eliane Rohde, Luis Eduardo Paim Leiria, Tiago Luiz Luz Salamoni, Joyce Yukie Yamakawa Garbin, Arthur Pereira Hutz, Mara Helena |
dc.subject.por.fl_str_mv |
Varfarina |
topic |
Varfarina CYP2C9 VKORC1 ASPH TTR |
dc.subject.eng.fl_str_mv |
CYP2C9 VKORC1 ASPH TTR |
description |
Warfarin is an oral anticoagulant prescribed to prevent and treat thromboembolic disorders. It has a narrow therapeutic window and must have its effect controlled. Prothrombin test, expressed in INR value, is used for dose management. Time in therapeutic range (TTR) is an important outcome of quality control of anticoagulation therapy and is influenced by several factors. The aim of this study was to identify genetic, demographic, and clinical factors that can potentially influence TTR. In total,422 patients using warfarin were investigated. Glibenclamide co-medication and presence of CYP2C9*2 and/or *3 alleles were associated with higher TTR, while amiodarone, acetaminophen and verapamil co-medication were associated with lower TTR. Our data suggest that TTR is influenced by co-medication and genetic factors. Thus, individuals in use of glibenclamide may need a more careful monitoring and genetic testing (CYP2C9*2 and/or *3 alleles) may improve the anticoagulation management. In addition, in order to reach and maintain the INR in the target for a longer period, it is better to discuss dose adjustment in office instead of by telephone assessment. Other studies are needed to confirm these results and to find more variables that could contribute to this important parameter. |
publishDate |
2020 |
dc.date.issued.fl_str_mv |
2020 |
dc.date.accessioned.fl_str_mv |
2023-11-14T03:23:29Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/other |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/267096 |
dc.identifier.issn.pt_BR.fl_str_mv |
1415-4757 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001158568 |
identifier_str_mv |
1415-4757 001158568 |
url |
http://hdl.handle.net/10183/267096 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Genetics and molecular biology. Ribeirão Preto. Vol. 43, no. 1 suppl. 2 (2020), e20190025, 5p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/267096/2/001158568.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/267096/1/001158568.pdf |
bitstream.checksum.fl_str_mv |
d41d8cd98f00b204e9800998ecf8427e c26f90d63e539bb3ab12260add46adb6 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225103928721408 |